MaxCyte Investor Presentation Deck

SPL Partnerships Offer Significant Revenue Upside, Particularly in Commercial Higher Value Partnership NPV Influencing Factors: • Large indications - greater ● royalty revenues or early achievement of sales-based milestones • Instrument & consumables - Higher utilization Significant upside in commercial revenue opportunity $200 $100 *10-year NPV **Weighted based on the expected split of commercial programs in Year 6 (assuming earliest approval); Assumes first 5-years of standard ten-year biotech sales curve $0 Example Partnerships NPV* Assumes 6 programs per SPL launching 1 year apart, 2 fail in preclinical, 4 enter clinical, and 1 reaches commercial ~$165M $147 $18 Higher Value Partnership While pre-commercial revenues are comparable, commercial revenues can vary significantly ~$53M $37 $16 ~$85M 13 $69 $16 Weighted Average NPV** Commercial Pre-Commercial Numbers are illustrative as an example and not specific to one SPL Partnership ● M MaxCyte Influencing Factors: Small indications - lower sales royalties or longer time period to realize commercial milestones ● Lower Value Partnership NPV Conservative commercial milestones - Smaller opportunity Instrument & consumables - Lower utilization Lower-bound estimate per Partnership © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation